查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401901

2030 年神經診斷市場預測：按產品、最終用戶按症狀和地區進行全球分析

Neurodiagnostics Market Forecasts to 2030 - Global Analysis By Product, By Condition End User, By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球神經診斷市場規模為 86 億美元，預計到 2030 年將達到 162 億美元，預測期內複合年成長率為 9.3%。

神經診斷學是指專注於評估和監測神經系統結構和功能的醫學診斷領域。為了診斷和評估癲癇、中風和神經退化性疾病疾病等神經系統疾病，我們使用各種非侵入性方法，如腦電圖 (EEG)、磁振造影(MRI)、電腦斷層掃描(CT) 和神經傳導研究。 - 使用侵入性方法。神經診斷在理解和管理影響大腦和神經系統的疾病方面發揮著重要作用。

帕金森氏症基金會公佈的資料顯示，2021年，美國估計有93萬人患有帕金森氏症，預計2030年將增加至120萬人。

神經系統疾病增加

隨著阿茲海默症、癲癇和多發性硬化症等疾病的全球負擔日益加重，人們對準確診斷工具的需求不斷成長，以促進早期檢測和有效管理。神經診斷技術，包括先進的成像方式和電生理測試，在深入了解神經系統的結構和功能方面發揮著至關重要的作用。此外，人們對早期診斷重要性的認知不斷提高，加上神經診斷技術的不斷進步，正在推動市場向前發展。

神經診斷設備高成本

神經診斷設備的高成本是神經診斷市場的主要抑制因素。神經診斷中使用的先進技術，例如先進的影像和監測設備，價格昂貴。這種高成本是神經診斷工具普及的障礙，特別是對於小型和預算有限的設施。此外，這種經濟負擔可能會限制尖端神經診斷技術的獲取，阻礙全面神經學評估的可能性，並阻礙神經診斷市場的整體成長。

神經診斷設備的技術進步

持續的技術創新，例如高解析度成像技術、用於遠端監控的穿戴式設備以及用於資料分析的人工智慧應用的開發，提高了診斷準確性和患者照護。這些進步為醫療專業人員提供了對神經系統疾病更全面的了解。隨著神經診斷技術的發展，提高診斷準確性、簡化工作流程和改善患者治療效果的潛力正在增加，從而推動了市場的進一步採用和擴張。

醫療專業人員缺乏認知

儘管神經診斷技術不斷進步，但醫療保健專業人員在理解和認知方面可能存在巨大差距。這種知識的缺乏可能會導致創新神經診斷程序和工具的延遲採用或利用不足。此外，認知不足會妨礙神經系統疾病的及時診斷和治療並影響患者的治療結果。

COVID-19 的影響：

COVID-19 的爆發對神經診斷市場產生了重大影響。封鎖、選擇性手術的限制以及醫療資源的重新分配減少了常規神經診斷測試。此外，患者因擔心感染疾病而不願去醫療機構就診，進一步阻礙了市場。然而，大流行加速了遠端醫療和遠端監控解決方案的採用，為神經診斷市場提供了機會。

診斷和成像系統產業預計將在預測期內成為最大的產業。

由於技術進步以及對精確和非侵入性診斷工具的需求不斷成長，診斷和成像系統領域預計將在預測期內主導神經診斷市場。磁振造影(MRI)、電腦斷層掃描 (CT) 和正子斷層掃描 (PET) 等先進影像技術有助於準確的神經系統診斷。此外，神經系統疾病發生率的增加凸顯了診斷和影像系統在市場上的重要性。

頭痛疾病領域預計在預測期內複合年成長率最高

預計在預測期內，頭痛疾病領域的神經診斷市場將顯著成長。頭痛（包括偏頭痛）盛行率的增加、意識的提高以及針對頭痛疾病的診斷技術的進步等因素促成了這種擴張。隨著醫療保健提供者優先考慮為頭痛患者提供準確的診斷和個體化治療計劃，針對該細分市場量身定做的神經診斷工具和程序的需求預計將增加，從而推動整體市場成長。

佔有率最大的地區：

預計在預測期內，北美將保持其在神經診斷領域的市場主導地位。該地區受益於完善的醫療基礎設施、先進的技術以及大量的研發投資。此外，神經系統疾病的日益普及、人口高齡化和意識的提高也促進了對神經診斷服務的持續需求。產業領導者的存在和有利的法規環境進一步加強了北美在神經診斷市場的地位。

複合年成長率最高的地區：

預計亞太地區神經診斷市場將顯著成長。人口快速成長、醫療意識提高以及神經系統疾病增加等因素正在推動對先進診斷技術的需求。該地區各國政府正在投資衛生基礎設施、促進研究和開發並促進技術採用。由於對醫療保健品質和可及性的日益重視以及高齡化，亞太地區神經診斷市場預計將顯著擴大。

免費客製化服務

如果您訂閱此報告，我們將為您提供以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球神經診斷市場：依產品

  • 介紹
  • 診斷/影像系統
    • 血管造影術系統
    • 電腦斷層掃描 (CT) 掃描儀
    • 腦電圖（EEG）系統
    • 肌電圖 (EMG) 設備
    • 磁振造影（MRI）系統
    • 腦磁圖 (MEG) 設備
    • 正子斷層掃描 (PET) 掃描儀
    • 超音波影像成像系統
    • 其他診斷/影像系統
  • 臨床診斷設備
    • 新一代定序設備
    • 聚合酶連鎖反應（PCR）裝置
    • Sanger序器
    • 其他臨床診斷設備
  • 試劑及消耗品
    • 抗體
    • 緩衝液
    • 酵素、蛋白質、胜肽
    • 培養基/血清
    • 探測
    • 溶劑
    • 其他試劑及消耗品
  • 其他產品

第6章全球神經診斷市場：依情況

  • 介紹
  • 神經退化性疾病
  • 癲癇
  • 頭痛症
  • 睡眠失調
  • 其他條件

第7章全球神經診斷市場：依最終使用者分類

  • 介紹
  • 醫院
  • 門診治療中心
  • 診斷實驗室和影像中心
  • 神經中樞
  • 研究機構和學術機構
  • 其他最終用戶

第8章全球神經診斷市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • GE Healthcare
  • Advanced Brain Monitoring, Inc
  • Bio-Rad Laboratories
  • Canon, Inc.
  • F. Hoffmann-La Roche AG
  • Fujifilm Corporation
  • GE Healthcare
  • Hitachi Ltd.
  • Hoffman-La Roche AG
  • Koninklijke Philips NV
  • Lifelines Neuro Company LLC
  • Mitsar Co. Ltd.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • QIAGEN NV
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
Product Code: SMRC24421

According to Stratistics MRC, the Global Neurodiagnostics Market is accounted for $8.6 billion in 2023 and is expected to reach $16.2 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Neurodiagnostics refers to the field of medical diagnostics that focuses on the assessment and monitoring of the nervous system's structure and function. It involves various non-invasive and invasive techniques, such as electroencephalography (EEG), magnetic resonance imaging (MRI), computed tomography (CT), and nerve conduction studies, to diagnose and evaluate neurological disorders, including epilepsy, stroke, and neurodegenerative diseases. Neurodiagnostics plays a crucial role in understanding and managing conditions affecting the brain and nervous system.

According to the data published by the Parkinson's Foundation, in 2021, an estimated 9,30,000 people were living with Parkinson's disease in the United States 2020, and this number is predicted to increase to 1,2 million by 2030.

Market Dynamics:

Driver:

Increasing incidence of neurological disorders

With a rising global burden of conditions such as Alzheimer's disease, epilepsy, and multiple sclerosis, there's an increased demand for precise diagnostic tools to facilitate early detection and effective management. Neurodiagnostic techniques, including advanced imaging modalities and electrophysiological studies, play a pivotal role in providing insights into the structure and function of the nervous system. Additionally, growing awareness of the importance of early diagnosis, coupled with continuous technological advancements in neurodiagnostics, propels the market forward.

Restraint:

High cost of neurodiagnostic devices

The high cost of neurodiagnostic devices stands as a significant restraint in the neurodiagnostics market. The sophisticated technologies utilized in neurodiagnostics, including advanced imaging equipment and monitoring devices, are costly. This elevated cost poses a barrier to the widespread adoption of neurodiagnostic tools, particularly for smaller healthcare facilities or those with budget constraints. Moreover, this financial burden can limit accessibility to cutting-edge neurodiagnostic technologies, hindering the potential for comprehensive neurological assessments and impeding the overall growth of the neurodiagnostics market.

Opportunity:

Technological advancements in neurodiagnostic devices

Continuous innovation, such as the development of high-resolution imaging techniques, wearable devices for remote monitoring, and artificial intelligence applications for data analysis, enhances diagnostic precision and patient care. These advancements offer healthcare professionals more comprehensive insights into neurological conditions. As neurodiagnostic technologies evolve, there is a growing potential for improved diagnostic accuracy, streamlined workflows, and enhanced patient outcomes, driving further adoption and expansion in the market.

Threat:

Lack of awareness among healthcare professionals

Despite the continuous advancements in neurodiagnostic technologies, a notable gap in understanding and awareness may exist among healthcare practitioners. This knowledge deficit can lead to the delayed or underutilized adoption of innovative neurodiagnostic procedures and tools. Additionally, inadequate awareness may hinder the timely diagnosis and management of neurological disorders, impacting patient outcomes.

COVID-19 Impact:

The COVID-19 pandemic has significantly impacted the neurodiagnostic market. Lockdowns, restrictions on elective procedures, and reallocation of healthcare resources have led to a decline in routine neurodiagnostic testing. Additionally, patient reluctance to visit healthcare facilities due to infection concerns has further hindered the market. However, the pandemic has accelerated the adoption of telehealth and remote monitoring solutions, offering opportunities for the neurodiagnostic market.

The Diagnostic & Imaging Systems segment is expected to be the largest during the forecast period

The diagnostic and imaging systems segment is poised for dominance in the neurodiagnostics market during the forecast period due to technological advancements and the growing demand for precise and non-invasive diagnostic tools. Advanced imaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), contribute to accurate neurodiagnosis. Additionally, the increasing incidence of neurological disorders emphasizes the significance of diagnostic and imaging systems on the market.

The headache disorders segment is expected to have the highest CAGR during the forecast period

During the forecast period, the headache disorders segment is anticipated to experience substantial growth in the neurodiagnostics market. Factors such as the increasing prevalence of headaches, including migraines, growing awareness, and advancements in diagnostic technologies specific to headache disorders are contributing to this expansion. As healthcare providers prioritize accurate diagnosis and personalized treatment plans for individuals suffering from headaches, the demand for neurodiagnostic tools and procedures tailored to this segment is expected to rise, driving the overall growth of the market.

Region with largest share:

North America is poised to maintain its market dominance in the neurodiagnostic sector during the forecast period. The region benefits from a well-established healthcare infrastructure, technological advancements, and significant investments in research and development. Additionally, the increasing prevalence of neurological disorders, a growing aging population, and higher awareness levels contribute to the sustained demand for neurodiagnostic services. The presence of major industry players and a favorable regulatory environment further solidify North America's position in the neurodiagnostic market.

Region with highest CAGR:

The Asia Pacific region is positioned for substantial growth in the neurodiagnostic market. Factors such as a burgeoning population, rising healthcare awareness, and increasing incidences of neurological disorders drive the demand for advanced diagnostic technologies. Governments in the region are investing in healthcare infrastructure, fostering research and development, and promoting technological adoption. With a growing emphasis on healthcare quality and accessibility, coupled with a rising aging population, the Asia Pacific neurodiagnostic market is expected to witness significant expansion.

Key players in the market:

Some of the key players in Neurodiagnostics Market include GE Healthcare, Advanced Brain Monitoring, Inc, Bio-Rad Laboratories, Canon, Inc., F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi Ltd., Hoffman-La Roche AG, Koninklijke Philips N.V., Lifelines Neuro Company LLC, Mitsar Co. Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, QIAGEN N.V., Siemens Healthineers and Thermo Fisher Scientific Inc.

Key Developments:

In November 2023, QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research.

In October 2023, QIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market, and providing distributable companion diagnostic test kits for the global market.

In May 2022, Bruker launched an innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its preclinical magnetic resonance imaging (MRI) portfolio. The new range of Maxwell 7 Tesla and 9.4 Tesla magnets eliminates the need for liquid helium or nitrogen refills while offering high-field sensitivity and resolution for advanced preclinical MRI and PET/MR research.

Products Covered:

  • Diagnostic & Imaging Systems
  • Clinical Diagnostic Instruments
  • Reagents & Consumables
  • Other Products

Conditions Covered:

  • Neurodegenerative Diseases
  • Epilepsy
  • Headache Disorders
  • Sleep Disorders
  • Other Conditions

End Users Covered:

  • Hospitals
  • Ambulatory Care Centers
  • Diagnostic Laboratories & Imaging Centers
  • Neurology Centers
  • Research Laboratories & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurodiagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostic & Imaging Systems
    • 5.2.1 Angiography Systems
    • 5.2.2 Computed Tomography (CT) Scanners
    • 5.2.3 Electroencephalogram (EEG) Systems
    • 5.2.4 Electromyography (EMG) Devices
    • 5.2.5 Magnetic Resonance Imaging (MRI) Systems
    • 5.2.6 Magnetoencephalography (MEG) Devices
    • 5.2.7 Positron emission tomography (PET) Scanners
    • 5.2.8 Ultrasound Imaging Systems
    • 5.2.9 Other Diagnostic & Imaging Systems
  • 5.3 Clinical Diagnostic Instruments
    • 5.3.1 Next-generation Sequencing Instruments
    • 5.3.2 Polymerase Chain Reaction (PCR) Instruments
    • 5.3.3 Sanger Sequencers
    • 5.3.4 Other Clinical Diagnostic Instruments
  • 5.4 Reagents & Consumables
    • 5.4.1 Antibodies
    • 5.4.2 Buffers
    • 5.4.3 Enzymes, Proteins, & Peptides
    • 5.4.4 Media & Sera
    • 5.4.5 Probes
    • 5.4.6 Solvents
    • 5.4.7 Other Reagents & Consumables
  • 5.5 Other Products

6 Global Neurodiagnostics Market, By Condition

  • 6.1 Introduction
  • 6.2 Neurodegenerative Diseases
  • 6.3 Epilepsy
  • 6.4 Headache Disorders
  • 6.5 Sleep Disorders
  • 6.6 Other Conditions

7 Global Neurodiagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Ambulatory Care Centers
  • 7.4 Diagnostic Laboratories & Imaging Centers
  • 7.5 Neurology Centers
  • 7.6 Research Laboratories & Academic Institutes
  • 7.7 Other End Users

8 Global Neurodiagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 GE Healthcare
  • 10.2 Advanced Brain Monitoring, Inc
  • 10.3 Bio-Rad Laboratories
  • 10.4 Canon, Inc.
  • 10.5 F. Hoffmann-La Roche AG
  • 10.6 Fujifilm Corporation
  • 10.7 GE Healthcare
  • 10.8 Hitachi Ltd.
  • 10.9 Hoffman-La Roche AG
  • 10.10 Koninklijke Philips N.V.
  • 10.11 Lifelines Neuro Company LLC
  • 10.12 Mitsar Co. Ltd.
  • 10.13 Natus Medical Incorporated
  • 10.14 Nihon Kohden Corporation
  • 10.15 QIAGEN N.V.
  • 10.16 Siemens Healthineers
  • 10.17 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Neurodiagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neurodiagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Neurodiagnostics Market Outlook, By Diagnostic & Imaging Systems (2021-2030) ($MN)
  • Table 4 Global Neurodiagnostics Market Outlook, By Angiography Systems (2021-2030) ($MN)
  • Table 5 Global Neurodiagnostics Market Outlook, By Computed Tomography (CT) Scanners (2021-2030) ($MN)
  • Table 6 Global Neurodiagnostics Market Outlook, By Electroencephalogram (EEG) Systems (2021-2030) ($MN)
  • Table 7 Global Neurodiagnostics Market Outlook, By Electromyography (EMG) Devices (2021-2030) ($MN)
  • Table 8 Global Neurodiagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) Systems (2021-2030) ($MN)
  • Table 9 Global Neurodiagnostics Market Outlook, By Magnetoencephalography (MEG) Devices (2021-2030) ($MN)
  • Table 10 Global Neurodiagnostics Market Outlook, By Positron emission tomography (PET) Scanners (2021-2030) ($MN)
  • Table 11 Global Neurodiagnostics Market Outlook, By Ultrasound Imaging Systems (2021-2030) ($MN)
  • Table 12 Global Neurodiagnostics Market Outlook, By Other Diagnostic & Imaging Systems (2021-2030) ($MN)
  • Table 13 Global Neurodiagnostics Market Outlook, By Clinical Diagnostic Instruments (2021-2030) ($MN)
  • Table 14 Global Neurodiagnostics Market Outlook, By Next-generation Sequencing Instruments (2021-2030) ($MN)
  • Table 15 Global Neurodiagnostics Market Outlook, By Polymerase Chain Reaction (PCR) Instruments (2021-2030) ($MN)
  • Table 16 Global Neurodiagnostics Market Outlook, By Sanger Sequencers (2021-2030) ($MN)
  • Table 17 Global Neurodiagnostics Market Outlook, By Other Clinical Diagnostic Instruments (2021-2030) ($MN)
  • Table 18 Global Neurodiagnostics Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 19 Global Neurodiagnostics Market Outlook, By Antibodies (2021-2030) ($MN)
  • Table 20 Global Neurodiagnostics Market Outlook, By Buffers (2021-2030) ($MN)
  • Table 21 Global Neurodiagnostics Market Outlook, By Enzymes, Proteins, & Peptides (2021-2030) ($MN)
  • Table 22 Global Neurodiagnostics Market Outlook, By Media & Sera (2021-2030) ($MN)
  • Table 23 Global Neurodiagnostics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 24 Global Neurodiagnostics Market Outlook, By Solvents (2021-2030) ($MN)
  • Table 25 Global Neurodiagnostics Market Outlook, By Other Reagents & Consumables (2021-2030) ($MN)
  • Table 26 Global Neurodiagnostics Market Outlook, By Condition (2021-2030) ($MN)
  • Table 27 Global Neurodiagnostics Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 28 Global Neurodiagnostics Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 29 Global Neurodiagnostics Market Outlook, By Headache Disorders (2021-2030) ($MN)
  • Table 30 Global Neurodiagnostics Market Outlook, By Sleep Disorders (2021-2030) ($MN)
  • Table 31 Global Neurodiagnostics Market Outlook, By Other Conditions (2021-2030) ($MN)
  • Table 32 Global Neurodiagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Neurodiagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 34 Global Neurodiagnostics Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 35 Global Neurodiagnostics Market Outlook, By Diagnostic Laboratories & Imaging Centers (2021-2030) ($MN)
  • Table 36 Global Neurodiagnostics Market Outlook, By Neurology Centers (2021-2030) ($MN)
  • Table 37 Global Neurodiagnostics Market Outlook, By Research Laboratories & Academic Institutes (2021-2030) ($MN)
  • Table 38 Global Neurodiagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.